Relief therapeutics « Terug naar discussie overzicht

quote:

eric_k4 schreef op 28 januari 2021 21:18:

Tribute no. xxx to DZR

About RLF-100

RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for Aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of Aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.

quote:

Frank312 schreef op 28 januari 2021 21:07:

KABOEM. op een goede manier.

quote:

Kleintje66 schreef op 28 januari 2021 21:43:

Knettergek daar:
finance.yahoo.com/quote/GBR?p=GBR

quote:

Rotmeo schreef op 28 januari 2021 21:48:

[...]
Als we dat toch hadden geweten...pfffff

quote:

eric_k4 schreef op 28 januari 2021 21:18:

Tribute no. xxx to DZR

About RLF-100

RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for Aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of Aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.

quote:

Kleintje66 schreef op 28 januari 2021 23:16:

Deze morgen even in de gaten houden.
finance.yahoo.com/quote/PED/community...